{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-005470","form_type":"8-K","ticker":"FDMT","cik":"0001650648","company_name":"4D Molecular Therapeutics, Inc.","filed_at":"2026-01-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.763231+00:00","generated_at":"2026-05-16T11:22:25.525383+00:00","sec_items":["2.02","5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"4D Molecular Therapeutics reports ~$514M cash; President/COO resigns, CEO assumes President role; new director appointed","bullets":["Fariborz Kamal resigned as President/COO effective Dec 31, 2025; transitions to part-time Chief Technical Advisor.","CEO David Kirn appointed President as of Jan 1, 2026, in addition to CEO role.","Glenn Sblendorio appointed to Board as Class I director effective Jan 5, 2026, serving on Compensation and Science/Technology Committees.","Preliminary cash, cash equivalents and marketable securities ~$514M as of Dec 31, 2025 (unaudited, subject to closing).","Mr. Sblendorio received initial option for 45,000 shares at $7.30 exercise price; annual cash retainer of $40,000 plus committee fees."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-005470","json":"https://secwatch.observer/filing/0001193125-26-005470.json","markdown":"https://secwatch.observer/filing/0001193125-26-005470.md","text":"https://secwatch.observer/filing/0001193125-26-005470.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650648/000119312526005470/0001193125-26-005470-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650648/000119312526005470/fdmt-20251231.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:22:25.525383+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}